Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography
- PMID: 11206045
- DOI: 10.1097/00007691-200102000-00011
Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography
Abstract
A rapid, sensitive, and specific liquid chromatography method for the simultaneous determination of four protease inhibitors (indinavir, nelfinavir, ritonavir, and saquinavir) in human plasma is described. After a liquid-liquid extraction with terbutyl methyl ether and a sequential washing of the reconstituted sample with hexane, protease inhibitors are separated on a phenyl column using a simple binary mobile phase of ammonium acetate buffer:acetonitrile (48:52) (pH = 7.5) with an ultraviolet detection at 260 nm. The standard curves are linear in the range 0.025-1 microg/mL for saquinavir, 0.1-4 microg/mL for indinavir and nelfinavir, and 0.25-10 microg/mL for ritonavir, with an average recovery ranging from 79% to 99%, and with both low interday and intraday coefficients of variation (<15%). This assay is simple, rapid (15-minute interval between runs) , and useful for therapeutic monitoring of the protease inhibitors on a routine basis.
Similar articles
-
Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography.J Chromatogr B Biomed Sci Appl. 2001 Jun 15;757(2):325-32. doi: 10.1016/s0378-4347(01)00172-4. J Chromatogr B Biomed Sci Appl. 2001. PMID: 11417878
-
Simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir, and saquinavir in human plasma.Clin Chem. 2000 Jan;46(1):73-81. Clin Chem. 2000. PMID: 10620574
-
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography.J Chromatogr B Biomed Sci Appl. 2001 May 5;755(1-2):85-9. doi: 10.1016/s0378-4347(00)00617-4. J Chromatogr B Biomed Sci Appl. 2001. PMID: 11393736
-
The choice of HIV protease inhibitor: indinavir is currently the best option.Prescrire Int. 1999 Apr;8(40):55-60. Prescrire Int. 1999. PMID: 10848067 Review.
-
Penetration of HIV-1 protease inhibitors into CSF and semen.HIV Med. 2000 Jul;1 Suppl 2:18-22. doi: 10.1046/j.1468-1293.2000.00002.x. HIV Med. 2000. PMID: 11737368 Review. No abstract available.
Cited by
-
Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.Br J Clin Pharmacol. 2005 Oct;60(4):390-403. doi: 10.1111/j.1365-2125.2005.02456.x. Br J Clin Pharmacol. 2005. PMID: 16187971 Free PMC article. Clinical Trial.
-
Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women.Antimicrob Agents Chemother. 2004 Feb;48(2):632-4. doi: 10.1128/AAC.48.2.632-634.2004. Antimicrob Agents Chemother. 2004. PMID: 14742224 Free PMC article. Clinical Trial.
-
High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.Clin Pharmacokinet. 2005;44(12):1267-78. doi: 10.2165/00003088-200544120-00005. Clin Pharmacokinet. 2005. PMID: 16372824 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources